INTERMOUNTAIN MEDICAL CENTER
The Sunshine Act requires manufacturers to report payments to teaching hospitals as institutions, separately from payments to individual physicians. These figures are money reported to the hospital itself — most of it research funding and grants, not compensation to any named doctor.
- Total reported
- $15.9M
- Transactions
- 1,848
- Companies
- 40
- Average per transaction
- $8,609
Who reported the payments
| Edwards Lifesciences | $2,017,137 |
| Regeneron | $1,715,420 |
| Fresenius USA Manufacturing, Inc. | $1,370,454 |
| Bristol Myers Squibb | $1,348,768 |
| Merck | $1,107,952 |
| CSL Behring | $877,158 |
| Novartis | $825,408 |
| AbbVie | $715,588 |
| Boehringer Ingelheim | $511,580 |
| Roche Products Limited | $495,505 |
| Medtronic | $481,257 |
| Takeda Pharmaceuticals U.S.A., Inc. | $446,322 |
| Amgen | $442,426 |
| E.r. Squibb & Sons, L.L.C. | $436,478 |
| Organ Recovery Systems, Inc. | $416,372 |
| Hoffmann-la Roche Limited | $336,127 |
| Cvrx, Inc. | $255,811 |
| Gilead | $238,493 |
| Pfizer | $161,813 |
| Servier Bioinnovation | $108,293 |
| Array Biopharma Inc | $102,011 |
| Livanova USA, Inc. | $96,734 |
| Opgen, Inc. | $88,068 |
| Meridian Bioscience Inc. | $81,160 |
| Acutus Medical, Inc. | $80,500 |
| Astellas Pharma Global Development | $80,058 |
| Boston Scientific | $77,126 |
| Neuropace, Inc. | $75,720 |
| Janssen Research & Development, LLC | $71,923 |
| Sumitomo Pharma America, Inc. | $60,204 |
| Immedica Pharma US, Inc. | $58,207 |
| Sterilmed, Inc. | $58,174 |
| Olympus America Inc. | $54,404 |
| Pi-cardia, Inc. | $52,600 |
| Procyrion, Inc. | $50,195 |
| Braincool, Inc. | $50,000 |
| Applied Medical Technology Inc | $49,289 |
| Genentech, Inc. | $48,469 |
| Med-el Corporation | $47,960 |
| W. L. Gore & Associates, Inc. | $44,686 |